Dental Implants After Cancer Treatment: What the Numbers Show

Two recent meta-analyses are worth quoting rather than paraphrasing. The first, published in Clinical Oral Investigations in 2021, pooled 2,602 implants placed in 660 head and neck cancer patients, 1,637 of those implants in irradiated jaws. Survival came out at 91.9% in irradiated patients after an average of about 40 months, against 97% in non-irradiated patients after about 38 months.

The second, published in Clinical Oral Implants Research in 2025 and covering the literature from 2021 to 2024, found 85.6% survival in irradiated patients against 90.0% in non-irradiated ones. Note what happens when you put the two side by side: they disagree about the absolute figures and agree about the direction and rough size of the gap — somewhere around five points. That is what honest evidence looks like in a field where patients, doses and follow-up periods differ, and it is more useful to you than a single confident number would be.

Two things follow. A survival figure in the high eighties or low nineties is not a coin flip, and it is the kind of number where planning moves the outcome more than luck does. And these figures describe radiation to the head and neck. Radiation delivered to a breast, a prostate or a lung does not irradiate your jaw, and this page is not about your case if that is your history — your medical history still matters, but for other reasons.

Osteoradionecrosis is the complication behind the caution: irradiated bone has a diminished blood supply and heals poorly, and surgery in it can leave an area of bone that does not recover. In the 2021 pooled analysis, osteoradionecrosis occurred in 11 cases across the population studied — an incidence of 3%. That is neither negligible nor the majority outcome, and both halves of that sentence matter when you are deciding.

The number that changes your personal risk most is not in any published average: it is the radiation dose that actually reached the part of your jaw where an implant would go. Your radiation oncologist holds the treatment plan that shows it, and that document tells us more than any general statement about head and neck radiation ever will. Requesting it is one of the first things we do, with your permission.

Patients often ask about hyperbaric oxygen, which has been used before and after implant placement in irradiated jaws for decades. The honest answer from the pooled data is that its impact on implant survival was not statistically significant in the 2021 analysis. We mention it because you will read about it, and because a treatment that has not demonstrated a benefit in pooled data should not be sold to you as insurance.

The same 2021 analysis found that waiting more than twelve months between the end of radiotherapy and implant placement appeared beneficial, and that implants placed inside the first year carried a higher failure risk. The wider literature commonly recommends at least six months, on the reasoning that the acute radiation effects on bone and soft tissue need that long to settle. Twelve months is the figure with pooled evidence behind it.

It is worth reframing that wait as part of the treatment rather than a delay before it. The interval is when tissue quality is assessed properly, when any remaining dental disease is dealt with, when nutrition and oral hygiene are rebuilt after a brutal year, and when the scan that will drive the surgical plan is taken in tissue that has stopped changing week to week. A plan drawn on a jaw that is still settling is a plan that gets redrawn.

The 2025 analysis adds a design consideration: implant failure risk was higher in grafted bone than in native bone. In an irradiated jaw, that argues for approaches that anchor into the bone you still have rather than building new bone first — tilted implants in a full-arch design, or, where the upper jaw has lost too much, zygomatic anchorage into the cheekbone. Which of those fits, if any, is a scan-and-examination question rather than a website question.

Chemotherapy on its own is less studied than radiation, and less alarming in the data that exists. What the 2025 analysis did find is that among irradiated patients, those who also received chemotherapy carried a greater risk of implant failure than non-irradiated patients — radiochemotherapy is harder on the result than radiation alone. During active chemotherapy, elective oral surgery generally waits for blood counts to recover, and that is your oncology team's call to make rather than ours.

For a great many cancer patients, though, the deciding factor is not the chemotherapy at all. It is the bone-protective infusions given alongside it. The ADA's position is that dental implants are contraindicated in patients on oncology antiresorptive agents — the high-dose intravenous bisphosphonates and denosumab used for bone metastases and myeloma — and the same conversation covers antiangiogenic drugs such as bevacizumab, sunitinib, sorafenib and everolimus. That subject has its own page, because it catches people who were never told it applied to them.

If you are about to begin treatment rather than finishing it, the priority inverts. A full dental examination with radiographs before therapy starts, and any necessary invasive work completed before the first dose, is the single most useful thing you can do for your future options. Once high-dose antiresorptive therapy has begun, the door narrows considerably.

The plan starts outside this office. With your permission we ask your oncologist and radiation oncologist for the treatment summary, the radiation dose map, the current medication list, and their view on timing. That correspondence is not a formality: the difference between a jaw that received a modest scattered dose and one that sat in the primary field is the difference between a routine case and one we would approach very differently, and neither is visible from the outside.

Then the ordinary work happens: an examination, a 3D CBCT scan, and an itemized written plan. For a post-radiation case that plan is more explicit than most about what is being accepted — the survival figures above, the healing risk, the longer follow-up interval, and what happens if an implant does fail, which is a question every patient in this position is entitled to have answered before rather than after.

And sometimes the plan is that implants are not the right answer, now or at all. When that is our view you will get it plainly, with the reason, along with what we would do instead — because a well-made removable prosthesis in a jaw that cannot safely take implants is a better outcome than an implant that fails in irradiated bone. If you would like a second opinion on advice you have already received, that is a consultation we are glad to give, including the possibility that the advice was right.